Experimental therapeutics: targeting the redox Achilles heel of cancer [0.03%]
实验性癌症治疗：针对癌症的氧化还原阿喀琉斯之踵
Christopher M Cabello,Warner B Bair rd,Georg T Wondrak
Christopher M Cabello
Reactive oxygen species (ROS) have recently emerged as promising targets for anticancer drug discovery. Constitutively elevated levels of cellular oxidative stress and dependence on mitogenic and anti-apoptotic ROS signaling represent a spe...
Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors [0.03%]
原发性脑肿瘤的小分子和抗体化疗方法
Herbert B Newton
Herbert B Newton
High-grade primary brain tumors remain refractory to conventional treatment approaches, including radiotherapy and cytotoxic chemotherapy. Molecular neuro-oncology has now begun to clarify the transformed phenotype of these malignant tumors...
Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy [0.03%]
特异性靶向CD4+CD25+FoxP3+调节性T细胞以增强癌症免疫治疗疗效
Rich-Henry Schabowsky,Shravan Madireddi,Rajesh Sharma et al.
Rich-Henry Schabowsky et al.
CD4+CD25+FoxP3+ T-regulatory (Treg) cells are vital to the maintenance of peripheral self tolerance and are implicated in tolerance to foreign antigens. Increasing evidence shows that Treg cells may also play an important role in immune eva...
Dirk Nagorsen,Eckhard Thiel
Dirk Nagorsen
The application of highly specific mAbs with minimal side effects in cancer therapy was, for a long time, a major goal for many clinical oncologists. Since their arrival in the clinical setting, mAbs have come to represent a standard therap...
Joseph Baar
Joseph Baar
Advances have been made in breast cancer therapy, in both the adjuvant and metastatic settings. For example, in the adjuvant setting, genomic studies of breast cancer tissues have identified women with estrogen receptor-positive tumors who ...
Adam M Farkas,Tina M Kilgore,Michael T Lotze
Adam M Farkas
Marlies Wakkee,H Bing Thio
Marlies Wakkee
Biogen Idec Inc, following its acquisition of Fumapharm AG, is developing BG-12 (Panaclar, BG-00012, FAG-201), an oral second-generation fumarate derivative, for the potential treatment of multiple sclerosis (MS). In January 2007, a phase I...
Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases [0.03%]
药物再评价：CNTO-1275，一种针对IL-12/IL-23p40的单抗，用于炎症疾病的治疗
Bianca Maria Wittig
Bianca Maria Wittig
Centocor Inc is developing CNTO-1275 (ustekinumab), a subcantaneous mAb against the p40 subunit of IL-12 and IL-23, for the potential treatment of inflammatory diseases such as psoriasis, psoriatic arthritis, multiple sclerosis (MS) and Cro...
Andreas Boker,Alexa B Kimball,Gabriela Rolz-Cruz
Andreas Boker
Psoriasis is a chronic inflammatory skin disorder that can cause substantial disability. The recognition of psoriasis as an immunologically mediated disease led to the development of agents that specifically target key steps in the patholog...
J Kenneth Baillie
J Kenneth Baillie
Severe sepsis will affect more than 870,000 individuals in the US this year, and has a mortality of approximately 30%. The pathophysiology of sepsis is believed to involve a complex cascade of inflammation, endothelial dysfunction, microthr...